- Q1 2024 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2024€20.8Earnings
- Q4 2023 Syndax Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2024€22.4 (+4.67%)Earnings
- Syndax Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 21, 2024
- Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Syndax Pharmaceuticals Inc to Host ASH Investor Event TranscriptDec 11, 2023
- Q3 2023 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2023€13.8 (+6.15%)Earnings
- Syndax Pharmaceuticals Inc to Host an Investor Call TranscriptOct 02, 2023
- Syndax Pharmaceuticals Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2023€18.6 (-0.53%)Earnings
- Syndax Pharmaceuticals Inc To Host Axatilimab AGAVE-201 Topline Data Call TranscriptJul 24, 2023
- Syndax Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Q1 2023 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2023€18.2Earnings
- Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Q4 2022 Syndax Pharmaceuticals Inc Earnings Call TranscriptFeb 28, 2023Earnings
- Syndax Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 21, 2023
- Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Syndax Pharmaceuticals Inc ASH Annual Meeting Data Update Call TranscriptDec 11, 2022
- Q3 2022 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2022€23.2 (-0.85%)Earnings
- Q2 2022 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2022€23.4 (+1.74%)Earnings
- Syndax Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Syndax Pharmaceuticals Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) TranscriptJun 02, 2022
- Syndax Pharmaceuticals Inc Targeted Oncology Panel at Citi Biopharma Co-Panel Day (Virtual) TranscriptMay 18, 2022
- Q1 2022 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2022€15.2 (-3.18%)Earnings
- Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Q4 2021 Syndax Pharmaceuticals Inc Earnings Call TranscriptMar 01, 2022€14.1 (+2.17%)Earnings
- Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Q3 2021 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 15, 2021€15.6 (+1.30%)Earnings
- Incyte Corp GVHD Update Call: Approval in cGVHD and Syndax Collaboration TranscriptSep 27, 2021
- Syndax Pharmaceuticals Inc and Incyte Corp Axatilimab Collaboration Call TranscriptSep 27, 2021
- Syndax Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2021
- Syndax Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 09, 2021€12.1Earnings
- Syndax Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Q1 2021 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 11, 2021€13.2 (+1.54%)Earnings
- Syndax Pharmaceuticals Inc - AUGMENT-101 Data Update And KOL Conference Call TranscriptApr 20, 2021
- Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 09, 2021
- Q4 2020 Syndax Pharmaceuticals Inc Earnings Call TranscriptMar 08, 2021€19.7 (+4.23%)Earnings
- Syndax Pharmaceuticals Inc ASH 2020 Axatilimab/cGVHD Conference Call TranscriptDec 06, 2020
- Syndax Pharmaceuticals Inc at Stifel Virtual Healthcare Conference TranscriptNov 18, 2020
- Q3 2020 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2020€14.3 (-2.72%)Earnings
- Syndax Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Q2 2020 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2020€12.4 (+0.81%)Earnings
- Syndax Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 09, 2020
- Q1 2020 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020€17 (-2.30%)Earnings
- Q4 2019 Syndax Pharmaceuticals Inc Earnings Call TranscriptMar 03, 2020€8.25 (-2.37%)Earnings
- Q3 2019 Syndax Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2019€6.3Earnings
- Syndax Pharmaceuticals Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 Syndax Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019€8.11 (+5.32%)Earnings
- Syndax Pharmaceuticals Inc at JMP Securities Life Science Conference TranscriptJun 20, 2019
- Syndax Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 21, 2019
- Q1 2019 Syndax Pharmaceuticals Inc Earnings Call TranscriptMay 06, 2019€6.5 (+2.36%)Earnings
- Q4 2018 Syndax Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2019€5.49 (-3.35%)Earnings
Syndax Pharmaceuticals Inc ASH Annual Meeting Data Update Call Transcript
Good day, everyone, and welcome to the Syndax ASH Annual Meeting Data Update Call. Today's call is being recorded.
At this time, I would like to turn the call over to Michael Metzger, Chief Executive Officer of Syndax Pharmaceuticals.
Thank you, operator, and thanks to everyone joining us this morning to review our revumenib data presented yesterday in 2 oral presentations at the 64th ASH Annual Meeting.
I want to begin by pointing out our forward-looking statements on Slide 2. Before we review the Phase I data for revumenib, our highly selective menin inhibitor and hear from 2 of our principal investigators, I would like to take a moment to outline Syndax goals for this year's ASH meeting on Slide 3. Our team is first and foremost focused on physician engagement and our disease awareness campaign at ASH.
As leaders in the menin inhibitor field, we continue to build the awareness of the benefits of using a menin inhibitor to treat mutant NPM1 and KMT2A acute
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)